Published in Br J Haematol on May 01, 1996
Biological implications of a 3 A structure of dimeric antithrombin. Structure (1994) 2.78
The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia (2004) 1.92
Thrombelastography. Blood Coagul Fibrinolysis (2001) 1.83
Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med (1990) 1.77
Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol (2001) 1.53
Thromboembolism and the combined oral contraceptive pill. Lancet (1995) 1.47
DdeI polymorphism in intron 5 of the ATIII gene. Nucleic Acids Res (1990) 1.44
Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol (2006) 1.34
Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (1997) 1.15
Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp) J Clin Invest (1994) 1.14
Prevalence of antithrombin deficiency in the healthy population. Br J Haematol (1994) 1.13
Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease. Eur Respir J (1998) 1.07
PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology (1992) 1.05
A comparison of randomized concurrent control groups with matched historical control groups: are historical controls valid? J Clin Oncol (1986) 1.03
Aryl hydrocarbon (Ah) receptor DNA-binding activity. Sequence specificity and Zn2+ requirement. J Biol Chem (1990) 1.03
Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women. J Cell Mol Med (2009) 0.98
The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol Chem Hoppe Seyler (1996) 0.96
Multiple DNA-binding factors interact with overlapping specificities at the aryl hydrocarbon response element of the cytochrome P450IA1 gene. Mol Cell Biol (1990) 0.92
Eosinophilia associated with adult T-cell leukemia/lymphoma. Cancer (1988) 0.89
A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies. Haemophilia (2009) 0.87
Evidence from sequence-tagged-site markers of a recent progenitor-derivative species pair in conifers. Proc Natl Acad Sci U S A (2000) 0.87
Mechanism of action of interferon-tau in the uterus during early pregnancy. J Reprod Fertil Suppl (1999) 0.87
Lesions of the patellar ligament. J Bone Joint Surg Br (1990) 0.86
A framework for genetic service provision for haemophilia and other inherited bleeding disorders. Haemophilia (2005) 0.86
Uptake of BRL 41897A, a C(7) alpha-formamido substituted cephalosporin, via the ferri-pyochelin transport system of Pseudomonas aeruginosa. J Antimicrob Chemother (1994) 0.85
Right heart obstruction due to intracavitary prolymphocytic leukemia. Am J Med (1986) 0.84
Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. Blood Coagul Fibrinolysis (1996) 0.84
Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer (1982) 0.84
Antithrombin Rouen-IV 24 Arg----Cys. The amino-terminal contribution to heparin binding. FEBS Lett (1990) 0.84
Some physical considerations in whole skin electron beam therapy. Med Phys (1983) 0.83
The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol (1991) 0.82
Investigation of copper-PTSM as a PET tracer for tumor blood flow. Int J Rad Appl Instrum B (1991) 0.82
Small cell carcinocythemia. Arch Pathol Lab Med (1999) 0.82
Antithrombin Dublin (-3 Val----Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS Lett (1990) 0.82
Statistical analysis of beta 2-microglobulin levels in sera of lung and GI tract cancer patients. Vox Sang (1980) 0.81
Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thromb Haemost (2000) 0.81
Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia (2008) 0.80
Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol (1998) 0.80
Penicillin-induced leukopenia. N Engl J Med (1982) 0.80
Antithrombin III: a database of mutations. Thromb Haemost (1991) 0.80
Structural interpretation of 42 mutations causing factor XI deficiency using homology modeling. J Thromb Haemost (2005) 0.80
Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. Eye (Lond) (1995) 0.79
Genetic testing in bleeding disorders. Haemophilia (2014) 0.79
Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy. Cancer Treat Rep (1983) 0.78
Mapping sequence specific DNA-protein interactions: a versatile, quantitative method and its application to transcription factor XF1. J Mol Biol (1997) 0.77
Insertions/deletions in the antithrombin gene: 3 mutations associated with non-expression. Thromb Haemost (1992) 0.77
Bovine granulocyte chemotactic protein-2 is secreted by the endometrium in response to interferon-tau (IFN-tau). Endocrine (1997) 0.77
Nephrotoxicity of streptozocin. Ann Intern Med (1982) 0.76
Recurrent pregnancy loss and thrombophilia. Ceylon Med J (2014) 0.76
Post-gamma globulin. II. Radioimmunoassay determination of levels of post-gamma globulin and beta 2-microglobulin. Clin Chim Acta (1983) 0.76
Carboplatin for advanced colorectal carcinoma: a phase II study. Cancer Treat Rep (1986) 0.76
Laboratory monitoring of haemostasis. Anaesthesia (2015) 0.76
Hodgkin's disease presenting as idiopathic thrombocytopenic purpura. Postgrad Med J (1984) 0.75
Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis. Am J Hematol (1987) 0.75
Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep (1983) 0.75
T-cell lymphoma occurring in the oropharynx. Cancer (1982) 0.75
Low dose vitamin K for excessively anticoagulated prosthetic valve patients. Mil Med (1982) 0.75
A novel polymorphism in intron 1a of the human factor VII gene (G73A): study of a healthy Italian population and of 190 young survivors of myocardial infarction. Br J Haematol (2000) 0.75
Inherited protein C deficiency, protein S deficiency and hyperhomocysteinaemia in a patient with hereditary spherocytosis. Clin Lab Haematol (1999) 0.75
Activated clotting factors in haemophilia (1840) Lancet (1987) 0.75
The PDQ database: what the primary care physician needs to know about current treatments for cancer and AIDS. J Med Pract Manage (1988) 0.75
Cisplatin and mitoguazone. An induction chemotherapy regimen in advanced head and neck cancer. Cancer (1988) 0.75
Compound heterozygosity for two beta chain variants: Hb S [beta 6(A3)Glu-->Val] and the high affinity variant Hb San Diego [beta 109(G11)Val-->Met]. Hemoglobin (1995) 0.75
Multimodality therapy for unresectable squamous cell carcinoma of the head and neck. Am J Clin Oncol (1985) 0.75
Examination of the factors Ac and Aeq for cylindrical ion chambers used in cobalt-60 beams. Med Phys (1979) 0.75
Hypersensitivity reactions to amsacrine. Cancer Treat Rep (1985) 0.75
Homozygous 2bp deletion in the human factor VII gene: a non-lethal mutation that is associated with a complete absence of circulating factor VII. Thromb Haemost (2000) 0.75
Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency. Blood Coagul Fibrinolysis (1997) 0.75
Reversible microangiopathic hemolytic anemia after mitomycin C. Cancer Chemother Pharmacol (1983) 0.75
Severe factor X deficiency due to a homozygous mutation (Cys364Arg) that disrupts a disulphide bond in the catalytic domain. Haemophilia (2006) 0.75
Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol (1983) 0.75
Factor VIII and IX inhibitors after exposure to heat-treated concentrates. Lancet (1987) 0.75
BMX bicycle injuries in hemophiliacs. Am J Dis Child (1987) 0.75
Changes in criteria for tumor response. J Clin Oncol (1985) 0.75
Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: effects of differing forms of hormonal contraception. Eur J Haematol (2003) 0.75
Bovine granulocyte chemotactic protein-2 is secreted by the endometrium in response to interferon-tau (IFN-τ). Endocrine (1997) 0.75
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma. J Clin Oncol (1983) 0.75
Genetics of haemostasis. Haemophilia (2012) 0.75
Empirical treatment of febrile, neutropenic patients with tobramycin and latamoxef. J Hosp Infect (1987) 0.75
Don't be a clot: a radiologist's guide to haemostasis including novel antiplatelet and anticoagulant therapies. Clin Radiol (2011) 0.75
Clinical predictors of response in metastatic germ cell tumors. Cancer (1988) 0.75
Induction chemotherapy with vinblastine, bleomycin, and cis-diamminedichloroplatinum in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg (1983) 0.75
A phase II trial of cisplatin and methylglyoxal bis-guanylhydrazone (MGBG) in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol (1986) 0.75
Enhanced bleomycin toxicity during acute renal failure. Cancer Treat Rep (1982) 0.75
Internal jugular vein thrombosis following in-vitro fertilization in a woman with protein S deficiency and heterozygosity for the prothrombin 3' UTR mutation, despite anticoagulation with heparin. Blood Coagul Fibrinolysis (2001) 0.75
Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer. Cancer Treat Rep (1986) 0.75
Significance of thrombocytosis. Lancet (1983) 0.75
Type I antithrombin deficiency: five novel mutations associated with thrombosis. Blood Coagul Fibrinolysis (1996) 0.75
Production, purification, and carboxy-terminal sequencing of bioactive recombinant bovine interferon-stimulated gene product 17. Biol Reprod (2000) 0.75
A model for calculating the effects of small inhomogeneities on electron beam dose distributions. Med Phys (1980) 0.75
Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization in a woman heterozygous for the prothrombin 3' UTR and factor V Leiden mutations. Am J Hematol (2003) 0.75
Concurrent Pneumocystis carinii and cytomegalovirus pneumonia after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1999) 0.75
Multiplex PCR for Detection of the Prothrombin 3'-UTR (G20210A) Polymorphism and the Factor V Leiden Mutation. Methods Mol Med (1999) 0.75
Phase II trial of bisantrene in advanced epidermoid carcinoma of the head and neck. Cancer Treat Rep (1984) 0.75
Pollen pool heterogeneity in jack pine (Pinus banksiana Lamb.): a problem for estimating outcrossing rates? Theor Appl Genet (1992) 0.75
Asymptomatic coinheritance of heterozygous plasminogen deficiency and the factor VLeiden mutation. Blood Coagul Fibrinolysis (1997) 0.75
Absorbed dose measurements using parallel plate polystyrene ionization chambers in polystyrene phantoms. Int J Radiat Oncol Biol Phys (1980) 0.75